Brentuximab Vedotin bulk supplier for pharma manufacturers

Brentuximab Vedotin 50 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 50 mg/vial

Reference Brands: Adcetris (USA/EU)

Brentuximab Vedotin is a monoclonal antibody–drug conjugate (ADC) that targets CD30-expressing cancer cells. It delivers a cytotoxic agent directly to malignant cells, helping to kill them while minimizing damage to normal tissue.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Brentuximab Vedotin — third party manufacturing & bulk supply

Brentuximab Vedotin 50 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Brentuximab Vedotin is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Brentuximab Vedotin listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Brentuximab Vedotin →

Back to Listing

Frequently Asked Questions

Brentuximab Vedotin is listed as Injection in 50 mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Brentuximab Vedotin is referenced against Adcetris (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.